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Endovascular therapy is now the treatment of choice for intracranial aneurysms (IAs) for
its efficacy and safety profile. The use of flow diversion (FD) has recently expanded to
cover many types of IAs in various locations. Some institutions even attempt FD as first
line treatment for unruptured IAs.The most widely used devices are the pipeline emboliza-
tion device (PED), the SILK flow diverter (SFD), the flow redirection endoluminal device
(FRED), and Surpass. Many questions were raised regarding the long-term complications,
the optimal regimen of dual antiplatelet therapy, and the durability of treatment effect. We
reviewed the literature to address these questions as well as other concerns on FD when
treating IAs.
Keywords: flow diversion, pipeline, intracranial aneurysm, FRED, Surpass, PED
INTRODUCTION
Endovascular therapy is now the treatment of choice for intracra-
nial aneurysms (IAs) for its efficacy and safety profile. Still,
many aneurysms such as large, giant, wide-necked, and fusiform
aneurysms are considered more challenging and less amenable to
traditional endovascular coiling (1). Stent-assisted coiling (SAC)
and balloon-assisted coiling (BAC) were alternative techniques
developed to deal with such complex aneurysms, but studies
have shown their less than expected efficacy given their high rate
of recanalization (2–5). The flow-diversion (FD) technique has
brought a feasible and effective solution. In addition, the use of
FD has recently expanded to cover many types of IAs in var-
ious locations. Some institutions even attempt FD as first line
treatment for unruptured IAs. The most widely used devices are
the pipeline embolization device (PED), the SILK flow diverter
(SFD), the flow redirection endoluminal device (FRED), and
Surpass. Many questions were raised regarding the long-term
complications (i.e., delayed bleeding and device migration), the
optimal regimen of dual antiplatelet therapy (APT), and the
durability of treatment effect. We reviewed the literature to
address these questions as well as other concerns on FD when
treating IAs.
FLOW-DIVERSION METHOD
The FD technique relies on a concept of endoluminal reconstruc-
tion of the parent artery and the aneurysm neck by excluding
the aneurysm from the circulation. The stasis of blood flow in
the aneurysm leads to an inflammatory response followed by
thrombosis and “healing” of the aneurysm while the stent acts
as a scaffold for neointimal proliferation and remodeling of the
parent vessel. Therefore, the FD approach is considered phys-
iologic as it restores the normal homeostasis. A recent study
showed that flow-diverter device (FDD) reduces the velocity in the
aneurysm sac significantly more than multiple“non-flow diverter”
stents, even though both dramatically reduce the aneurysmal fluid
movement (6). To break the communication between the parent
artery and the aneurysm while maintaining a patency of sidewall
branches, the device must fulfill two requirements: a low poros-
ity (metal-free to metal-covered area) and a high pore density
(number of pores per square millimeters for a given porosity)
(7, 8). However, sidewall branch occlusions do not always lead
to ischemia since collaterals may maintain flow to the dependent
area. Even more, when collaterals are not present, the increased
demand for tissue perfusion may, in some cases, generate a pres-
sure gradient sufficient to maintain an anterograde flow through
the device (7).
The technique involves navigating an FDD through the arterial
system and deploying it across the aneurysm neck. Proper deploy-
ment is essential as inadequate wall apposition may decrease the
flow with consequent thrombus formation at the interface fol-
lowed by thromboembolic events (8). Proper deployment and ade-
quate wall apposition can be achieved by balloon (Boston angio-
plasty (9), though not always needed. More so, the increased turbu-
lence along with the lytic enzymes released from platelet aggrega-
tion predisposes to a possible lysis of the aneurysmal wall that can
usually occur in the following days post-op (10). This may lead to
rupture and SAH if the aneurysm is not completely thrombosed.
After stent deployment, there are no data-driven guidelines on
optimal APT. Most of the time, the patient is maintained on
dual APT for 3–6 months followed by lifelong monotherapy.
In practice, the indication varies depending on the aneurysm loca-
tion (anterior vs. posterior), and parent artery/side vessels stenosis
(1, 8). The blood-thinning component makes FDD of limited
use in ruptured aneurysm, at least not before the aneurysm is
entirely secured. The heterogeneity of the response to APT, espe-
cially with clopidogrel, could explain the in-stent thrombosis on
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one hand, and the hemorrhagic events on the other. One study led
by Lee et al. showed that all cases of intraprocedural thrombosis
occurred in patients with poor response to antiplatelet treatment
(11). Delgado et al. found that pre-procedure P2Y12 reaction unit
(PRU) value of<60 (over-inhibition) was an independent predic-
tor of perioperative hemorrhagic events and a PRU value of >240
(under-inhibition) was an independent predictor of perioperative
ischemic events (12). Both a technically difficult procedure and
labile hypertension are independent risk factors of thromboem-
bolic and hemorrhagic complications. In practice, some authors
recommend loading the patient 10 days prior to the procedure
with 75 mg/day of clopidogrel (or another thienopyridine) and
81 mg/day of aspirin until 30–90% P2Y12 inhibition is achieved
(9). In our institution, Clopidogrel assays are checked at base-
line before the administration of Clopidogrel and then again just
before the procedure. The percentage of inhibition is calculated
and the dosage is adjusted to achieve a platelet inhibition between
30 and 90% before the procedure. Patients with resistance to Clopi-
dogrel are switched to Prasugrel. Dual APT is envisioned for at least
6 months, followed by lifelong monotherapy of aspirin (81 mg).
Table 1 | Indications and concerns regarding flow diversion treatment.
Indications for flow diversion Concerns
Diameter >10 mm Bifurcation aneurysm
Neck width >4 mm Small saccular aneurysm with
low recurrence risk after coiling
Complex morphology: fusiform,
dissecting
Recurrence after coiling
The FDDs offer the advantage of avoiding IA manipulation that
increases the rupture risk as well as avoiding any coil insertion that
may worsen the preexisting mass effect. The findings of Lylyk et al.
(13) and Szikora et al. (14) were consistent with this advantage as
they reported that improvement of mass effect symptoms occurred
after FD treatment. On the contrary, the inflammatory changes
inside the aneurysm may cause a transient worsening of the mass
effect that can be seen initially after the procedure, by increasing
the aneurysm size or perhaps by direct spread of the inflammation
to the surrounding parenchyma (15). A well-known yet poorly
understood complication is the rupture of previously silent IAs.
One reason could be the hemodynamic alteration of flow after PED
or SFD placement (16). Delayed hemorrhage is another unfavor-
able outcome whose risk factors are not fully elucidated. Evidence
shows that large size, complex geometry, and high aspect ratio
(>1.6) predispose to delayed hemorrhage (17). More so, Kuzmik
et al. highlighted the unpredictability of FD by showing that even
when the morphology and the location are similar, the treatment
outcomes may differ enormously (18). One final major area of
ambiguity is the delayed remote intracerebral hemorrhage (ICH),
explained by some as shower emboli with hemorrhagic conversion
and by others as a damping effect after FD that increases the pul-
satility of distal vasculature and leads to small arteriolar rupture
(15). As for the indications of FD (Table 1), it was used tradition-
ally for large and giant aneurysms (diameter>10 mm), wide-neck
aneurysms (neck width>4 mm), and aneurysms with a morphol-
ogy unsuitable for coiling (fusiform and dissecting). In theory, FD
can be used for any type of aneurysm but concerns remains about
its use in bifurcation-aneurysms and whether it is worth using in
small saccular aneurysms with low recurrence rate after coiling
(15) (for illustrative pictures of aneurysm treated with PED, check
Figures 1–6).
FIGURE 1 | Case 1.
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FIGURE 2 | Case 2.
FIGURE 3 | Case 3.
www.frontiersin.org February 2014 | Volume 5 | Article 21 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zanaty et al. Flow-diversion panacea or poison?
FIGURE 4 | Case 4.
FIGURE 5 | Case 5.
FIGURE 6 | Case 6.
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PIPELINE EMBOLIZATION DEVICE
The PED (ev3, Irvine, CA, USA) is a microcatheter-delivered, self-
expanding, cylindrical stent composed of a mesh of 48 individual
cobalt chromium and platinum strands. It has a low porosity, high
metal coverage, and is specifically designed for FD. It is available
in lengths up to 35 mm with diameters of 2.5–5 mm in 0.25 mm
increments.
This device once initially used for large and giant aneurysm has
been increasingly used for smaller and less complex ones. Recently,
PED has been shown in the treatment of large (>10 mm) sac-
cular unruptured aneurysms (UAs) to achieve higher occlusion
rate, fewer recanalization rate, and similar morbidity and mor-
tality than with traditional coiling (9). Another benefit of PED
when compared to coiling is the fewer cost when the aneurysm is
>0.9 cm3 and only one device is used (19). It is of highly impor-
tance to estimate the number of PED required as it affects the cost,
the safety, and the efficacy of the procedure (20).
In a systemic review of the literature involving 10 studies, Leung
et al. managed to pull out data on 414 patients with 448 IAs
treated with PED (1) (Table 2). The mean number of PED used
was 2 devices per IAs. The procedure-related complications were
IAs rupture, ischemic strokes, non-IA-related intracranial hem-
orrhages, worsening of mass effect, and femoral/retroperitoneal
hematomas. The overall symptomatic complication rate was
10.3% (46/447), of which 6.3% were exclusively intracranial vas-
cular events (ischemic or hemorrhagic). The procedure-related
mortality was 2.2% (9/413), mostly due to rebleeding. The mor-
bidity and mortality rate following treatment of UAs was much
lower than those following the treatment of ruptured ones (6.1
vs. 18.8%, 0.8 vs. 12.5%, respectively), but no statistical test was
applied in their study. The limited number of ruptured IAs in the
studies makes the difference in morbidity and mortality rates less
valid. Still, the authors advised against the use of PED in con-
text of ruptured IAs given the lack of evidence on its efficacy and
safety in the literature. The authors found that IAs that have been
previously stented posed a challenge to PED deployment, had a
higher rate of vascular complications and a lower rate of com-
plete obliteration. Thus, the previous findings should be taken
into consideration while planning PED treatment for previously
stented aneurysm. Complete obliteration was achieved in 82.8%
(293/354) at 6-month follow-up, which compares favorably with
SAC (21) and balloon-assisted embolization (22). However, a more
scientific comparison is needed before concluding. Fargen et al.
(16), in their review of reported complications associated with the
PED, found similar morbidity (5.3%) and mortality (1.3%) rates.
In another study, PED was used to treat complex, simple, wide-
necked, giant, small, fusiform, dissecting, and saccular aneurysms
(23). Technical deployment was successful in all cases. On aver-
age, the number of PED device used was 1.91 per aneurysm
(23). Reported symptomatic complications constituted 13.9% and
included thromboemboli, ICH, dissection, and death. Multiple
stents were used to ensure proper coverage and care was taken not
to cover the perforator with more than one stent.
Piano et al. managed to treat successfully 47 aneurysms with
Silk and 57 with PED without any technical failure (24). The mor-
bidity and mortality rate, including delayed complications were
both 3%. Follow-up after 6 months showed complete occlusion
in 85% of the cases. At 1-year follow-up, no recanalization was
observed.
On the other hand, some authors reported remarkably lower
rates of mortality and morbidity. Saatci et al. treated 251
aneurysms in 191 patients using PED with a morbidity rate of 1%
and a mortality rate of 0.5%. Similarly, Pistocchi et al. in a series
of 30 aneurysms beyond the circle of Willis reported no mortality
and a morbidity rate of 3.7% (25). Finally, Brinjikji et al. in their
meta-analysis of 29 studies, examined 1452 patients with 1654
IAs and found that the procedure-related morbidity and mortal-
ity with FDDs (both PED and SFD) were 5% (95% CI; 4–7%)
and 4% (95% CI; 3–6%), respectively, and the complete occlusion
rate to be 76% (95% CI; 70–81%) (26) (Table 2). They also noted
that treatment of posterior circulation aneurysm is more prone to
ischemic events, particularly perforator infarction when multiple
devices are used. Overall, the perforator occlusion risk was 3%.
Another major concern with PED stent is the higher risk of
spontaneous migration, which could be early or delayed, and
results in aneurysm rupture or ischemic events (27). It is best
managed by placing additional stents to achieve once again com-
plete coverage or even more precociously, by taking preventive
measures in the first place, such as using longer PEDs, achieving
complete expansion, avoiding dragging and stretching of the PED
that distorts and shortens the device, and finally using adjunctive
coiling to prevent any prolapse of the PED into the aneurysm (27).
SILK FLOW-DIVERTER
SILK stent (Balt Extrusion, Montmorency, France) is a self-
expanding flexible stent constructed of woven nitinol strands
Table 2 | Morbidity, mortality, and occlusion rates for FDDs as reported from case series, systemic reviews, and meta-analysis.
FDD used Morbidity rate (%) Mortality rate (%) Complete occlusion at
follow-up (%)
Leung et al. (systemic review) PED (1–3.2/patient) Ruptured and unruptured
aneurysms: 6.3
Ruptured and unruptured
aneurysms: 2.2
82.8
Ruptured only: 18.8 Ruptured only: 12.5
Unruptured only: 6.1 Unruptured only: 0.8
Saatci et al. PED (1.3/patient) 1 0.5 91.2
Brinjikji et al. (meta-analysis) PED and SFD 5 4 76
Pistocchi et al. PED and SFD 3.7 0 78.9
Briganti et al. (meta-analysis) PED and SFD 3.7 5.9 85
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and platinum microfilament with low porosity and high metal
coverage of 35% (28). It is available in 2–5 mm diameters and in
15–40 mm lengths.
Treatment with Silk has been shown to be efficacious, safe, with
reasonable morbidity and mortality. Silk was found in some stud-
ies to achieve similar occlusion rates to PED, but with the cost of
higher early complications (25, 29). Mortality rates for the device
reported from case series ranged from 0 to 8% and morbidity rates
from 3.9 to 15% (29–33). Complete aneurysm occlusion rates were
50–69% at 6-months follow-up, and one study of 26 aneurysms
reported an occlusion rate of 86% at 1 year (29). However, the
number of studies does not allow a fair head-to-head comparison
with PED.
A multicenter study enrolling 25 Italian centers evaluated 273
patients with 295 IAs that were treated with Silk or PED (10). The
trial included fusiform, large, giant, and wide-necked aneurysms.
Also, small aneurysms deemed untreatable by conventional coiling
were included in the study. The morbidity and mortality rate in
the anterior location were 2.3 and 3.5%, respectively. In the poste-
rior location, the reported morbidity and mortality rate were 5.4
and 19%, respectively. The overall mortality rate was 5.9% and the
morbidity rate was 3.7%. Hemorrhagic events occurred in 5.5% of
patients, of which 50% were device-related complications: seven
patients had delayed aneurysm rupture (two with SFD, five with
PED), and one patient had middle cerebral artery (MCA) perfo-
ration during PED retrieval after distal migration of the device.
The remaining seven had hemorrhagic events that were deemed
procedure-related such as iatrogenic vessel perforation and ICH
on APT.
Thromboembolic events occurred in 4.8% of patients and
included: side-branch occlusions (one with Silk, two with PED),
in-stent thrombosis (three with Silk, three with PED), and
procedure-related ischemia. The authors also noted a higher mor-
tality in the subgroup of intracavernous aneurysms (4%) treated
by FDD and in the small subgroup of patients with giant complex
aneurysm treated by coiling (35.7%; 5/14) (10). Thus, it is recom-
mended that extradural aneurysm be treated only if symptomatic
and in expert hands (10). Finally, failure of device deployment,
device mispositioning, in-stent aggregation, and other technical
complications occurred in 21.5% of the procedures without clin-
ical manifestations. This high rate may be related to the recent
introduction of the devices (10). At 3-month follow-up, complete
occlusion was achieved in 85% of patients. The remaining 15%
were exclusively aneurysms of the anterior circulation. Finally, the
authors conducted a meta-analysis of six studies, including their
own (13, 14, 30, 33, 34) that showed an overall morbidity rate of
6.2% (CI 95% 2.0–6.7%) and a mortality rate of 3.4% (CI 95% 2.4–
4.7%). The safety and efficacy of FD use in bifurcation aneurysms
remain unknown. So far, FD has been reserved for bifurcation
aneurysms that are not amenable to surgery and when other means
of endovascular treatment are deemed risky (35). A study was
recently published on PED treatment of 25 aneurysms located at
MCA bifurcation or M2 in case one of the bifurcating branches
or a distal branch originated directly from the aneurysm sac (35).
Follow-up (3–30 months) showed a complete occlusion rate of
84%. They had no mortality and an SAH as the only procedural
complication. Even with the limited number of cases and the lack
of long-term follow-up, the results are somewhat encouraging.
SURPASS FLOW-DIVERTER
The Surpass flow diverter (Surpass; Stryker Neurovascular, Fre-
mont, CA, USA) is a new device that comes in various diameters
and length so that most of the time, one single stent is sufficient
for aneurysm occlusion (8). The essential features of the device
are a low porosity, and a uniformly distributed high pore density
that remains constant regardless of the diameter. The advantage
of a single device use is the maintenance of a constant porosity
by alleviating the need of random telescoping of two implants.
This offers additional protection for side branches by allowing
a better control of porosity and pore density (8). In a study
of 37 patients, harboring 49 UAs, a single device was used to
treat each patient except in one case, where telescoping of two
devices had to be done to cover the whole diseased segment
of a giant fusiform basilar aneurysm (8). The study included:
large, giant, wide-necked, dissecting/fusiform, and blister-type
aneurysms. Recurrent or recanalized saccular aneurysms that have
been previously coiled and small aneurysms that were judged to
have a high risk of rupture were also included. In this study,
38 devices were used to treat 49 aneurysms, which means an
average of 0.8 devices per aneurysm. There was no failure of
device delivery. Complete occlusion was achieved in all 35-non-
bifurcation aneurysms. The higher occlusion rate in the study
could be due to the maintenance of pore density with the change
in diameter of the device, in contrast to PED and Silk (8). As
experimental studies have showed, a constant pore density over
the length of the aneurysm neck leads to a more efficient FD
and durable aneurysm occlusion (7). Still, this conclusion would
be premature given the absence of control group in the study.
Even more, the high proportion of small aneurysms included
in this study could have influenced the higher occlusion rate
and the lower complication rate (8). In comparison, none of
the 14 bifurcation-aneurysm received complete neck coverage,
and only 50% were occluded on follow-up after 6 months. As
for the complications, a clot formed in one case over the Sur-
pass stent and was successfully treated by intra-arterial abciximab.
Other complications were: small asymptomatic MCA perforation,
2 internal carotid artery traumatic dissections by the microwire
(one of which was noticed during the operation and success-
fully treated by Surpass). There was no major intraoperative
vasospasm or migration of the implant, and no periprocedural
mortality or significant morbidity. During follow-up, four patients
(10.4%) experienced transient ischemic events and one patient
(3%) developed a minor stroke 1 month after stopping clopido-
grel with persistent neurological deficit. Therefore, the morbidity
rate was comparable to coiling and SAC as well as to other FD
devices such as PED and Silk (36, 37) (Table 3). The major-
ity showed improvement or resolution of their symptoms while
the remaining remained stable. The authors concluded that Sur-
pass flow diverter is safe, reliable, and very effective given the
right indications. The main limitations of this single trial are
the small number of patients and the high proportion of small
aneurysms (37).
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Table 3 | Mortality, morbidity, and complete occlusion rate as reported
from case series.
Device Mortality
rate (%)
Morbidity
rate (%)
Complete
occlusion (%)
PED 0–6 0–9 76–91.2
SILK 0–8 3.9–15 69
FLOW REDIRECTION ENDOLUMINAL DEVICE SYSTEM
The FRED system (MicroVention, Tustin, CA, USA) is a new gen-
eration of FDDs used in the treatment of IAs. Diaz et al. reported
the first use of FRED in the western world, in their small trial of
13 patients with 14 IAs (38). They had no immediate complica-
tions or technical difficulties. However, the trial lacked follow-up
on long-term complications and angiographic results. The authors
viewed the ability of the device to maintain its internal shape when
navigating in tortuous and kinky cerebral vessels as an improve-
ment over the older generations of FDDs (38). The authors were
encouraged by the outcomes of the study.
NOVEL USE OF FLOW-DIVERSION DEVICES
Newly, PED was used for arterial deconstruction instead of recon-
struction by inducing a progressive thrombosis of the parent artery
that fed the aneurysm (39). In this case report, a patient with a
giant distal MCA aneurysm who refused open surgery did not
tolerate superselective balloon-occlusion test and catheterization
of the aneurysm for PED treatment was unattainable. PED was
used for a compromise between branch occlusion and FD. The
patient eventually tolerated the progressive thrombosis promoted
by PED. It was postulated that chronic ischemia favored the expres-
sion of vascular endothelial growth factor, thereby inducing the
development of a collateral network by angiogenesis, and restor-
ing the blood flow (39, 40). Nyberg et al. took advantage of the
unique property adherent to PED in order to salvage the MCA
after surgical clipping of the internal carotid artery aneurysm that
left the flow compromised in the MCA (41). The final configu-
ration of PED as well as the final radial forces are related to the
material properties of PED and, unlike other FDD, are opera-
tor dependent such as the more foreshortened the device is, the
greater its radial force (41). The diamond-like configuration of
the strands provides PED with high resistance to crushing; more
pressure is required to crush the device to its pre-deployment
configuration then to deploy it (41). PED was used to expand
the MCA against the clip, with the help eventually of balloon
angioplasty.
Flow-diversion is also being used for intracranial dissecting
aneurysms. In the acute phase, FD can be problematic. First, nav-
igation of the device through tortuous vessel is challenging. More
so, the patients have to be put under aggressive antiaggregation,
which could be problematic in case of rerupture and rebleeding
when the aneurysm is not completely secured. This risk of hem-
orrhage should be weighed against the risk of ischemic events. On
the other hand, FD offers the advantages of avoiding aneurysm
catheterization. In addition, the densely packed woven mesh slow
or avert the progression of the dissecting aneurysm by holding
the flap up against the wall and vessel remodeling (42). Therefore,
FDDs are being used effectively and with caution in the treatment
of acute dissecting aneurysms. Still, parent artery occlusion, when
feasible, remains the preferred and safest treatment option (42, 43).
CONCLUSION
Treatment of UAs with FDDs is safe and effective with high com-
plete occlusion rates. The procedure-related morbidity and mor-
tality varied in the literature, yet remained encouraging. Posterior
circulation aneurysms, previously stented aneurysm, bifurcation-
aneurysm, and multiple stent use may result in poorer outcomes.
These factors must be thought of when determining the type
of treatment. Careful manipulation of the device, proper device
deployment, and complete coverage of the neck help reduce the
procedure-related complications. The use of FD in recently rup-
tured IAs has not been solidly proven safe. More trials are needed
to clarify the management of aneurysms that failed treatment and
the management of clinical adverse outcomes as well as their pre-
vention. Finally, the remarkable efficacy that led recently to PED
use in smaller and less complex aneurysm should be challenged
in randomized controlled trials with traditional endovascular
coiling.
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